RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Today's 10-Q shows cash at $53 K as of June 30, so obviously they will need to raise money very soon. The dosing portion of the CX-1739 RD trial was completed in June and the trial formally completed July 11. On July 27 they amended the trial agreement with Duke University to include additional post-clinical trial costs of $120 K -


https://www.sec.gov/Archives/edgar/data/849636/000149315216012247/form10-q.htm


>>> Duke University Clinical Trial Agreement


On January 27, 2015, the Company entered into a Clinical Study and Research Agreement (the “Agreement”) with Duke University to develop and conduct a protocol for a program of clinical study and research at a total cost of $50,579, which was completed in March 2015 and charged to research and development expenses during the three months ended March 31, 2015. On October 30, 2015, the Agreement was amended to provide for a Phase 2A clinical trial of CX1739 at a cost of $558,268. During March 2016, a Phase 2A clinical trial at Duke University School of Medicine was initiated, with the dosing portion of the clinical trial completed in June 2016 and the clinical trial formally completed on July 11, 2016. On July 27, 2016, the Agreement was further amended to reflect additional post-clinical trial costs of $120,059, increasing the total amount payable under the Agreement to $678,327.

<<<